Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

Leica Microsystems Receives Award as Technology Leader

Frost & Sullivan recognizes subsidiary Bioptigen for their product innovation in OCT

Frost & Sullivan Best Practices Award 2015

Wetzlar, Germany. The research and consulting company Frost & Sullivan has recognized Leica Microsystems’ newly acquired Optical Coherence Tomography (OCT) company Bioptigen of Morrisville, North Carolina, USA, as a technology leader and pioneer of the North American ophthalmic imaging industry. The Frost & Sullivan Award ceremony took place January 13, 2016 in San Diego, USA.

In their appraisal, Frost & Sullivan calls attention to the value represented in Bioptigen’s OCT solutions: "Frost & Sullivan recognizes the enormous value addition Bioptigen’s Envisu Spectral Domain (SD)-OCT platform brings to ophthalmic imaging."

Particularly emphasized are the highly customizable imaging solutions for pre-clinical and clinical applications. Bioptigen is offering hand-held OCT imaging capabilities bringing OCT directly to the patient. Quick and sensitive real-time OCT imaging minimizes the challenges of comprehensive eye examinations with supine and non-compliant patients, such as infants and children. Bioptigen offers the world's only hand-held OCT solution approved by the FDA for use as an aid in the diagnosis of physiological and pathologic conditions of the eye.

Markus Lusser, President of Leica Microsystems, expressed his pride at the award: "Leica Microsystems is honored that Bioptigen has been selected for the Frost & Sullivan Award. It is tangible proof of the Bioptigen team’s dedication to creativity, innovation, and the constant exploration of growth potential in the vision healthcare market."

Bioptigen develops and manufactures innovative OCT systems and software and provides products for clinical as well as translational research applications globally. Bioptigen currently markets the Envisu OCT for pediatric ophthalmic imaging applications, and a family of OCT imaging products for vision science research. Notably, in December 2015, the company received FDA clearance for EnFocus, an innovative OCT ophthalmic imaging solution to upgrade surgical microscopes with intrasurgical OCT capabilities directly integrated in the light path of the microscope. Bioptigen was acquired by Leica Microsystems in 2015.

Share this article

Related Images

Bioptigen offers the world's only hand-held OCT solution approved by the FDA for use as an aid in the diagnosis of physiological and pathologic conditions of the eye.